RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. EBITDA

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$108.9B
P/E ratio
SummaryFinancials
Period EndEBITDA (Million USD)YoY (%)
Dec 31, 2024-26-100.64%
Dec 31, 20234,013-9.93%
Dec 31, 20224,456+53.24%
Dec 31, 20212,908-1.96%
Dec 31, 20202,966+127.35%
Dec 31, 20191,305+84.36%
Dec 31, 2018708+283.22%
Dec 31, 2017185+158.84%
Dec 31, 201671-117.63%
Dec 31, 2015-405-35.70%
Dec 31, 2014-629-26.42%
Dec 31, 2013-855-2210.12%
Dec 31, 201241-72.78%
Dec 31, 2011149-122.36%
Dec 31, 2010-666

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)